Trials | Usage of GM-CSF | Maximum dose of GM-CSF | Medication timea | Effective rate | Yearb |
---|---|---|---|---|---|
Seymour et al. [15] | subcutaneous injection | 5 μg/kg/day | 300 days | 100% (n = 1) | 1996 |
Kavuru et al. [16] | subcutaneous injection | 9μg/kg/day | 12 weeks | 75% (n = 4) | 2000 |
Seymour et al [17] | subcutaneous injection | 20μg/kg/d | 6–12 weeks | 43%(n = 14) | 2001 |
Bonfield et al. [18] | subcutaneous injection | 18 μg/kg/day | 12–48 weeks | 55% (n = 11) | 2002 |
Tazawa et al. [19] | inhalation therapy | 250 μg/day; every other week | 24 weeks | 100% (n = 3) | 2005 |
Venkateshiah et al. [20] | subcutaneous injection | 18 μg/kg/day | 12–52 weeks | 48% (n = 21) | 2006 |
Wylam et al. [21] | inhalation therapy | 500ugbid week-on, week-off | 3–68 weeks | 92%(n = 12) | 2006 |
Tazawa et al. [22] | inhalation therap | 250 μg/day d1-d8, d9-d14 no use of drugs × 6 cycles | 24 weeks | 62% (n = 39) | 2010 |
Spyros et al. [23] | inhalation therapy | 250μg qd 4 days-on, 4 days-off | 14–65 weeks | 100%(n = 6) | 2014 |
Tazawa et al. [24] | inhalation therapy | (125 μg bid d1-d8, d9-d14 no use of drugs × 6 cycles) + (125 μg qd d1-d4,d5-d14 no use of drugs× 6 cycles) | 24 weeks | 66%(n = 35 | 2014 |